| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_7b5d728d4890268356fcc07e6e53840c |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-5084
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2077 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/B82B3-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-60
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4365
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4743
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/H01J1-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-145
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-146
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4365
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-60 |
| filingDate |
2006-06-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_df8e4c2a334ae2ec7daa3868761212d7
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_aabba7c3bb729162d2eb7d4dea3d1a38 |
| publicationDate |
2006-12-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
CA-2611741-A1 |
| titleOfInvention |
Nanoparticulate clopidogrel and aspirin combination formulations |
| abstract |
The present invention is directed to compositions comprising a nanoparticulate clopidogrel and aspirin combination, or salts or derivatives thereof, having improved clopidogrel bioavailability. The nanoparticulate clopidogrel particles, and optionally the nanoparticulate aspirin particles, of the composition have an effective average particle size of less than about 2000 nm and are useful in the prevention and treatment of pathologies induced by platelet aggregation. The clopidogrel and aspirin particles may also be formulated as a controlled release polymeric coating or matrix drug delivery system. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2017037741-A1 |
| priorityDate |
2005-06-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |